Glycated albumin a new paradigm in better monitoring Type 2 diabetes complications as a short-term glycemin index

Abstract

Suresh Babu Kondaveeti, Anand Shaker Ivvala, R. Chidambaram

The metabolic disregulation of carbohydrates is the principal factor of diabetes, where high blood glucose levels persist which is the cause of diabetes complications, and that long-term control of blood glucose levels is required to avoid or lessen the damage caused by excess glucose. Monitoring blood sugar levels in individuals with diabetes mellitus is currently managed by a long-term testing. Albumin is the largest component of the plasma proteins, representing more than 80% of the total molecules and 60% of the total plasma protein concentration. It is replaced in the body approximately every 20-25 days, as there is a need of short-term marker glycated albumin (GA) will be the ideal marker for an intermediate index to measure glycation GA plays a double role in diabetes complications. In addition to being a marker for glycation, GA has been directly implicated for a role in several major complications of diabetes, including atherosclerosis, nephropathy, retinopathy and cognitive function. Levels of GA change more rapidly over time in response to changes in treatment than do levels of haemoglobin A1c (HbA1c). A recent survey of endocrinologists has demonstrated physician support for an intermediate index for glycemic control based on GA. With such a test available, doctors would recommend a substantial reduction in the level of self-monitoring blood glucose testing for their patients. The HbA1c test cannot effectively measure glycation within a 3-month period, during which time diabetes complications can advance if unchecked. There is a demonstrated need for an intermediate glycatio index to monitor diabetes. A test based on GA could provide a stable monthly index of glycemic control.